Dayawansa Sam, Abbas Salma O, Mantziaris Georgios, Dumot Chloe, Donahue Joseph H, Sheehan Jason P
Department of Neurological Surgery, University of Virginia, Charlottesville , Virginia , USA.
Department of Radiology, University of Virginia, Charlottesville , Virginia , USA.
Neurosurgery. 2023 Dec 1;93(6):1339-1345. doi: 10.1227/neu.0000000000002594. Epub 2023 Jul 12.
Stereotactic radiosurgery (SRS) is widely used to manage recurrent or residual nonfunctioning pituitary adenomas (NFPAs). Studies on the long-term volumetric response of NFPAs to SRS are lacking. Such a post-SRS volumetric study will allow us to set up appropriate radiographic follow-up protocols and predict tumor volumetric response.
Two providers independently performed volumetric analyses on 54 patients who underwent single-session SRS for a recurrent/residual NFPA. In the case of discrepancy between their results, the final volume was confirmed by an independent third provider. Volumetry was performed on the 1-, 3-, 5-, 7-, and 10-year follow-up neuroimaging studies.
Most patients showed a favorable volumetric response, with 87% (47/54) showing tumor regression and 13% (7/54) showing tumor stability at 10 years. Year 3 post-SRS volumetric results correlated (R 2 = 0.82, 0.63, 0.56) with 5-, 7-, and 10-year outcomes. The mean interval volumetric reduction was 17% on year 1; further interval volumetric reduction was 17%, 9%, 4%, and 9% on years 3, 5, 7, and 10, respectively.
Year 3 post-SRS volumetric response of patients with residual or recurrent NFPAs is predictive of their 7-10-year follow-up response. For patients demonstrating NFPA regression in the first 1-3 years, interval follow-up MRI's can likely be performed at 2-year periods unless otherwise clinically indicated. Further studies are needed to better define the volumetric response to adenomas more than a decade after SRS.
立体定向放射外科(SRS)被广泛用于治疗复发性或残留性无功能垂体腺瘤(NFPA)。目前缺乏关于NFPA对SRS长期体积反应的研究。这样一项SRS后的体积研究将使我们能够建立适当的影像学随访方案并预测肿瘤体积反应。
两名研究人员独立对54例接受单次SRS治疗复发性/残留性NFPA的患者进行了体积分析。如果他们的结果存在差异,最终体积由独立的第三方研究人员确认。在1年、3年、5年、7年和10年的随访神经影像学研究中进行体积测量。
大多数患者显示出良好的体积反应,87%(47/54)在10年时肿瘤缩小,13%(7/54)肿瘤稳定。SRS后第3年的体积测量结果与5年、7年和10年的结果相关(R² = 0.82、0.63、0.56)。第1年平均体积缩小率为17%;第3年、5年、7年和10年的进一步体积缩小率分别为17%、9%、4%和9%。
残留或复发性NFPA患者SRS后第3年的体积反应可预测其7至1年的随访反应。对于在最初1至3年显示NFPA缩小的患者,除非有其他临床指征,间隔期的MRI检查可能每2年进行一次。需要进一步研究以更好地明确SRS后十多年腺瘤的体积反应。